Predicting and overcoming radioresistance are crucial in radiation oncology, including in managing oral squamous cell carcinoma (OSCC). First, we used RNA-sequence to compare expression profiles of parent OML1 and radioresistant OML1-R OSCC cells in order to select candidate genes responsible for radiation sensitivity. We identified IRAK2, a key immune mediator of the IL-1R/TLR signaling, as a potential target in investigating radiosensitivity. In four OSCC cell lines, we observed that intrinsically low IRAK2 expression demonstrated a radioresistant phenotype (i.e., OML1-R and SCC4), and vice versa (i.e., OML1 and SCC25). Next, we overexpressed IRAK2 in low IRAK2-expression OSCC cells and knocked it down in high IRAK2-expression cells to examine changes of irradiation response. After ionizing radiation (IR) exposure, IRAK2 overexpression enhanced the radiosensitivity of radioresistant cells and synergistically suppressed OSCC cell growth both in vitro and in vivo, and vice versa. We found that IRAK2 overexpression restored and enhanced radiosensitivity by enhancing IR-induced cell killing via caspase-8/3-dependent apoptosis. OSCC patients with high IRAK2 expression had better post-irradiation local control than those with low expression (i.e., 87.4% vs. 60.0% at five years, $P = 0.055$), showing that IRAK2 expression was associated with post-radiation recurrence. Multivariate analysis confirmed high IRAK2 expression as
an independent predictor for local control (HR, 0.11; 95% CI, 0.016–0.760; P = 0.025). In conclusion, IRAK2 enhances radiosensitivity, via modulating caspase 8/3-mediated apoptosis, potentially playing double roles as a predictive biomarker and a novel therapeutic target in OSCC.

**Keywords: IRAK2, radioresistant, apoptosis, radiosensitization, oral squamous cell carcinoma**

**INTRODUCTION**

Radiotherapy (RT) is an essential treatment modality for managing patients with oral squamous cell carcinoma (OSCC) (1). However, cancer radioresistance restricts the clinical efficacy of RT. Although several genes and molecular pathways have been reported (2, 3), the molecular events leading to a radioresistant phenotype of OSCC remain mostly unknown. Therefore, exploring a novel targeted molecular marker that sensitizes tumors to ionizing radiation (IR) is crucial to overcome radioresistance and then decrease post-RT cancer recurrence.

RNA Sequencing (RNA-Seq) technology, widely used in studying whole-genome expression profiles, can help identify possible therapeutic targets (4). To search for genes potentially responsible for OSCC resistance that could predict radiosensitivity, we recently established a stable, radioresistant oral cancer cell subline (i.e., OML1-R) from its parent line (i.e., OML1) via step-by-step fractionated irradiations (5). Subsequently, we performed next-generation sequencing (NGS) and bioinformatics techniques to analyze post-IR gene expression between the two cell lines. Finally, we identified that IRAK2 was up-regulated in post-irradiated parental OML1 cells, but not in radioresistant OML1-R cells, implicating that the IRAK2 gene might play a role in the process of radiosensitivity in OSCC.

IRAK2 (Interleukin-1 receptor associated kinase 2) is a component of the interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) signaling cascade (6). Known to act as an adaptor in the TLR-MyD88-TRAF6 complex, IRAK2 could enable the downstream activation of NF-κB and thereby regulating inflammation (7). Notably, IRAK2 also participates in the regulation of cellular apoptosis via inducing the FADD-dependent caspase-8 apoptotic pathway to trigger the Yersinia-induced macrophage cell death (8). Besides, IRAK2 has been recognized as a contributor to ER stress-induced cell death via IRE1/CHOP signaling (9). Recently, one family member of IRAK2, i.e., IRAK1, has been reported to play a role in the processes of TLR signaling (10) and intrinsic radioresistance, suggesting a potential chemoradiotherapy target (11). However, the function and biologic effects of IRAK2 in association with intrinsic/acquired radioresistance in the context of solid cancers, including OSCC, remain mostly unknown.

Hence, in the present study, we present new insight into the significance of IRAK2 in radiation response, therefore, tested the role of IRAK2 in OSCC, focusing on exploring its potential function and molecular mechanism in mediating radiosensitization. Our data indicated that IRAK2 is an attractive target, in both predictive and therapeutic aspects, for radioresistant OSCC because the overexpression of IRAK2 may contribute to enhanced/restore IR-induced tumor cell killing.

**MATERIALS AND METHODS**

**Chemicals and Reagents**

Antibodies against IRAK2, cleaved caspase-8, cleaved caspase-3, NF-κB-p65, and C/EBP homologous protein (CHOP) were purchased from the Cell Signaling Technology (Beverly, MA). Processes of storage, manipulation, and analysis obeyed the manufacturer’s instructions.

**Cell Lines and Cell Culture**

SCC4 and SCC25 were bought from American Type Culture Collection (ATCC; Manassas, VA) and cultured in DMEM/F12 containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 2 mM L-glutamine. Parental (OML1) and acquired-radioresistant (OML1-R) cell lines were established and maintained in RPMI1640 containing 10% FBS, 1% penicillin-streptomycin, and 2 mM L-glutamine, as previously reported (5, 12). Briefly, we constructed OML-1R from parental OML-1 cells by using fractionated irradiations. A fraction size of 5 Gy was delivered per 5-7 days till every 80% confluent of irradiated cells. By ten fractions, a total of 50 Gy were delivered on parental OML-1 cells to construct OML-1R cells. Then, we applied a 10-Gy single shot to validate the level of acquired radioresistance of OML-1R cells before further experiments [10]. Briefly, a total of 1 x 10^3 cells were seeded on a 6-cm plate before irradiation. The next day, cells were irradiated with 10 Gy and then cultured for another 2-3 days.

**Patient Samples and Radiotherapy Details**

From Jan. 2007 to Dec. 2014, we retrospectively identified 41 patients with pathological stage I-II OSCC (i.e., pT1-2N0M0 status) (12, 13). The reason to choose this population was that OSCC patients with microscopic residual disease (R1) or close surgical margins of ≤5 mm (R0) have an increased risk for local failure even if the resected tumor was staged as pT1-2N0M0 and therefore were subjected to postoperative RT according to guidelines (1). All patients received radical surgery and postoperative RT. Indications of RT for these patients were positive or close surgical margin (i.e., ≤5 mm), as mentioned previously (13). All OSCC patient samples (i.e., formalin-fixed paraffin-embedded pathological blocks) were retrospectively re-confirmed, and tumor-burden-enriched regions (i.e., >70% tumor-content area) were re-sliced, re-stained, and retrieved for bench experiments, as previously reported (12).
Postoperative RT was delivered using the intensity-modulated radiotherapy (IMRT) technique (14). Irradiation volumes were designed according to the principle of radiotherapy (15), in terms of high-, moderate-, and low-risk planning target volume (PTV). Notably, total doses of RT to the high-risk PTV (i.e., the oral surgical bed and high-risk lymph-drainage basins) were ranged from 60 Gy to 66 Gy by using a conventional fraction size of 1.8-2.0 Gy (6-MV photons).

**Research Database of Clinical Outcomes**

For coding post-irradiation clinical outcomes, we used the Dalin Prospective-coding Cancer Registration Database. This database was a regular national-audit cancer database for oncological research. Regular audits were conducted by the multimodality committee of the Health Promotion Administration, Ministry of Health and Welfare, Taiwan (16). At the latest audit in 2018, the overall data-consisting rate was 99.5%. For each involved patient, the following clinicopathological factors were retrospectively retrieved from the database: age, RT dose, pathologic stage, clinical stage, surgical margin, and postoperative adjuvant chemotherapy (17–19). All data were independently validated by a radiation physician and analyzed by a biostatistician according to methods described in the statistical section, as previously reported (12).

**Illumina MiSeq System**

We used TRIZOL to isolate total RNAs according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA). Next, we used the Illumina MiSeq (Illumina, San Diego, CA) to conduct RNA-Seq. The mapped reads (i.e., Reads Per Kilobase Million [RPKM]) were applied to indicate gene expression levels; this value was used to calculate the average expression level for each gene between paired OML1 and OML1-R cell lines treated with or without IR. Gene expression profiles of both cells were obtained from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE165585). First, we selected genes that exhibited a statistically significant difference of higher than 1.5-fold between OML1 and OML1-R cells after IR. Next, we filtered out lowly expressed transcripts by using an absolute value of RPKM < 2. Then, we identified eight genes of IRAK2, KLK6, NSMF, SCO1, TRIP13, LMBR1, SCARB1, and FANCD2. Finally, we investigated IRAK2 because IRAK2 showed the maximum fold change of gene expression.

**Colony Formation Assay**

OSCC cell lines were treated with indicated irradiation doses of 0, 4, or 10 Gray (Gy) by using 6-MV photons (Varian linear accelerator, US), as previously reported (12). Notably, to provide effective dose delivery, a 0.5-cm bolus was placed over both the upper and down-sides of the culture dishes, just like a sandwich design (5). Briefly, cells were cultured in a specific medium for more than 80% flucency. Next, we trypsinized and plated the cells to produce a single-cell suspension in another culture dish. Then, irradiation was delivered per protocol in the irradiating arm; the control arm had no irradiation. At seven days after irradiation, colonies (defined as groups of >50 cells) were fixed and stained with 0.05% crystal violet for further visual quantification. For quantifying cell number, irradiated cells were stained with 0.4% crystal violet (Sigma) and counted at OD580 by using a spectrophotometer (GeneQuant 1300, GE Healthcare, UK) (20).

**Western Blotting**

We lysed cells with 100µl of PRO-PREP Protein Extraction Solution according to the manufacturer’s protocol. Then, protein samples (50 µg/well) were separated by 12% SDS-PAGE electrophoresis and transferred to PVDF membranes at 260 mA for about 90 minutes, as reported previously (21). Briefly, membranes were blocked with 5% non-fat dried milk in 1X TBS-T buffer (for 1 hour at room temperature) and probed with primary antibodies (diluted with 5% non-fat milk in 1X TBST), followed by HRP-labeled secondary antibodies (also diluted with 5% non-fat milk in 1X TBST). Finally, bands were visualized by using electrochemiluminescence detection reagents (Millipore, Billerica, MA). Quantification was performed by using the image-J software (National Institute of Health, NIH, Bethesda, MD).

**RNA Extraction and Quantitative Real-Time–Polymerase Chain Reaction (qRT-PCR)**

Total RNA samples were extracted by using the TRIZOL (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions and previously reported (12). Briefly, we used DNase I (amplification grade, Invitrogen) to treat 1µg of total RNA before first-strand cDNA synthesis by using reverse transcriptase (Superscript II RT, Invitrogen). Then, PCR reactions were performed by using the ABI StepOne real-time PCR system (Applied Biosystems, Foster City, CA). For PCR, specific primers were used accordingly. The relative expression of IRAK2 was estimated by using the comparative Ct method. The following primers were used: IRAK2, forward, CGAGCTGGGATGTCAGTG; reverse, GCCCAATACGACCAAATCC. The following primers were used: GAPDH, forward, AGCCACATCGCTCAGATGG; reverse, CATCAAGGCTGGAATTGTCAAC; GAPDH, forward, AGCCACATCGCTCAGATGG; reverse, CATCAAGGCTGGAATTGTCAAC. The following primers were used: IRAK2, forward, GCCCAATACGACCAAATCC. The following primers were used: IRAK2, forward, GCCCAATACGACCAAATCC.

**Flow Cytometry Analysis**

Apoptosis was measured by using the FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ) with combined-agent Apoptosis Detection Kit (BD Bioscience, Heidelberg, Germany). Annexin V, Fluorescein isothiocyanate (FITC), and 7-aminoactinomycin D (7AAD) were applied and analyzed following the manufacturer’s instruction. The cells were treated with or without 4 Gy for 48 hours and collected by trypsinization. Cell pellets were resuspended in 400 µl 1X binding buffer and then stained with 5.0 µl annexin V-FITC as well as 2.5 µl 7-AAD for 20 min at room temperature in the dark and then analyzed via flow cytometry.

**Transient Overexpression**

First, cells were plated in a 6-cm culture dish. The plasmid for human IRAK2 (Myc-DDK-tagged) ectopic expression was purchased from Origene (Rockville, MD). We transfected...
pCMV6-IRAK2 plasmid into OSCC cells by using Lipofectamine 2000® (Invitrogen, Carlsbad, CA) and Opti-MEM medium, according to the manufacturer’s protocols. Cells were finally selected for stable clones by using the medium that contained 400µg/ml Geneticin (G418, Invitrogen).  

**Transient Knockdown**  
The human IRAK2 shRNA sequence was purchased from the National RNAi Core Facility at Academia Sinica, Taiwan (clone ID: TRCN0000418431). Lentiviral constructs that expressed IRAK2-shRNA were subcloned into pLKO.1-puro plasmid, a lentiviral vector for cDNA expression (Sigma-Aldrich, St. Louis MO). All lentiviral vectors were transducted into 293T cells by using Lipofectamine 2000 reagent according to the manufacturer’s instructions. For lentiviral transduction, cells were treated with 8 µg/ml Polybrene (Sigma-Aldrich). Viral supernatants were added to the cell culture medium for 48 hours. The transduced cells were selected with 3 ug/ml puromycin (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA).  

**Immunohistochemistry**  
Paraﬁn-embedded oral tumor sections were stained with an anti-IRAK2 antibody (monoclonal; Abnova, Taiwan) and then detected by using the Super Sensitive™ Polymer-HRP IHC detection system (Biogenex, San Ramon, CA), according to the manufacturer’s instructions. Antigens were retrieved by using EDTA buffer (pH9.0) at 100°C for 25 minutes. Then, the slides were incubated at room temperature with 1:50-diluted IRAK2 antibody for 1 hour, followed by washing with 1XTRS-T. Finally, the sections were incubated with diaminobenzidine (DAB) for 5 minutes to generate signals. The pathologist evaluated stained slides of individual patients. The staining intensity of IRAK2 over the cell membrane or cytoplasmic region was scored by using a scale ranging from 0–3 and percentages (0-100%). The score was a continuous variable, ranging from 0–300. The value was calculated by using the following formula: 1 × (percentage of weakly stained cells, i.e., 1+) + 2 × (percentage of moderately stained cells, i.e., 2+) + 3 × (percentage of strongly stained cells, i.e., 3+). The median IHC score of 110 was applied as a cut-off value to differentiate high or low expression.  

**In Vivo Tumorigenesis**  
We used male 6-week-old athymic nude mice (BALB/cAnN.Cg-Foxn1nu/Crl) for the in vivo xenograft experiment. Null vector OML1-R cells and stable IRAK2-transfected OML1-R cells (2 × 10^7 cells) were suspended in 200 ul PBS. Then, these cells were injected subcutaneously into the left and right flanks of each mouse, respectively (n = 3 in each group). Tumor volume was monitored and quantified with a tumor volume growth ratio (final volume/initial volume). For exploring the role of IRAK2 in radiosensitivity in vivo, the control and IRAK2-overexpressed groups were designed (n = 3 in each group). IR treatment was started 40 days after cancer cells transplantation. As a similar IR protocol of cell irradiation (5), we delivered IR every four days. A total dose of 50 Gy was given in 10 fractions (Varian linear accelerator, US). All animal protocols were performed according to the instructions of the Institutional Animal Care and Use Committee of National Chung Cheng University (IACUC no.1060703).  

**RESULTS**  
**IRAK2 Affected the Sensitivity of OML1 and ML1-R Cells to IR**  
Clonogenic assay conﬁrmed a higher radiosensitivity of OML1 than that of OML1-R cells. When treated with the same dose of IR, especially 10 Gy, OML1-R cells exhibited a higher survival fraction than that of parental OML1 cells, suggesting that OML1-R is relatively resistant to IR treatment (Figure 1A). To identify genes whose expressions were altered after exposure to radiation, we utilized RNA-seq to assess the expression pattern of genes between paired parent (OML1) and radioresistant (OML1-R) cells lines treated with or without IR. By comparing the expression proﬁles of the two cell lines, we hypothesized that radiation exposure could activate genes responsible for the radiosensitivity process. By using reads per kilobase transcript per million mapped reads (RPKM) to estimate gene expression, we identiﬁed 19 genes that exhibited statistically signiﬁcant differences of higher than 1.5-fold between OML1 and OML1-R cells after IR (Figure 1B). Of these, we found that IRAK2 showed the maximum fold change of gene expression (Figure 1B). Hence, we chose IRAK2 as our target for further functional analysis because it plays a vital role in regulating innate immunity (22) and may have great potential in predicting radiation response of OSCC cells. The data showed that the RPKM value of IRAK2 expression of the OML1-R was lower than that of OML1 cell lines whether control or IR treatment (Figure 1C). Real-time quantitative PCR (qPCR) and Western blotting analysis revealed that both mRNA and protein expressions of IRAK2 were up-regulated in irradiated OML1 cells compared with IR-treated OML1-R cells (Figures 1D, E).
IRAK2 Overexpression Restored Radiosensitivity by Enhancing IR-Induced Cell Killing and Apoptosis in Radioresistant OML1-R Cells

To evaluate whether IRAK2 influences the sensitivity of radioresistant OSCC to IR, we overexpressed IRAK2 in OML1-R cells, which demonstrated an intrinsically low level of IRAK2. As shown in Figure 2A, IRAK2-overexpressed OML1-R cells exhibit a higher radiosensitivity than that of control OML1-R cells (P = 0.0100), suggesting a role of IRAK2 in the process of restoring radiosensitivity in radioresistant OSCC.

Apoptosis has been well known as a biological indicator for measuring cellular radiosensitivity (23). IRAK2-overexpressed OML1-R cells showed more apoptosis than that of control OML1-R cells, especially after 4Gy IR treatment; quantitative data for apoptosis rate were consistent with this phenomenon (Figure 2B).

IRAK2 is critical for apoptosis through FADD-dependent recruitment of caspase-8 activation (8) and the endoplasmic reticulum (ER) stress-induced IRE-1/CHOP signaling pathway (9). After 72 hours of exposure to 4-Gy IR, IRAK2-overexpressed OML1-R cells had higher levels of cleaved caspase-8 and caspase-3, but not NF-κB and CHOP, than that of control OML1-R cells (Figure 2C). To further confirm these results, we applied z-IETD-FMK, a caspase-8 inhibitor, to pretreat IRAK2-overexpressed OML1-R cells. Our results revealed that z-IETD-FMK attenuated the overexpression of IRAK2-induced apoptosis, as shown by significant decreases in cleaved caspase-8 and cleaved caspase-3 (Figure 2D). These results simultaneously indicated that IRAK2 overexpression re-sensitizes OML1-R cells to IR treatment via enhancing caspase-8- and caspase-3-dependent cell apoptosis.

IRAK2 Knockdown Decreased OSCC Radiosensitivity and IR-Induced Apoptosis

To further address whether IRAK2 is sufficient to induce apoptosis and alter cellular radiosensitivity, we quantified the expression of IRAK2 in four OSCC cell lines, finding that OML1 and SCC25 cells exhibited higher expression of IRAK2 (Figure 3A). IRAK2-specific shRNA was delivered into OML1 and SCC25 cells to knock down IRAK2 expression. Both IRAK2-knockdown OML-1 and SCC25 cells demonstrated higher survival rates after exposure to IR when compared with their control cells (P = 0.0009 and 0.0577, respectively; Figure 3B). To examine the apoptotic effects of IRAK2 shRNA combined with radiation in OML1 and SCC25 cell lines. The results revealed that in both cell lines, shRNA-IRAK2 cells were diminished radiation-induced apoptosis compared with their control cells after IR exposure (Figure 3C). IRAK2 silencing also decreased the expression of cleaved caspase-8 and -3 in both two types of OSCC cancer cells when compared with their control cells (Figure 3D). These data indicated that IRAK2 knockdown in OSCC cells strikingly attenuated radiosensitivity via inhibiting caspase-8/3-mediated apoptosis.
IRAK2 Overexpression Enhanced IR-Induced Tumor Regression in Radioresistant OSCC Xenografts

To evaluate the radiosensitization potential of IRAK2 in vivo, we established a nude mice xenograft model that injected IRAK2-overexpressed OML1-R cells. IRAK2-overexpressed xenografts demonstrated an apparent reduction in tumor volume when compared with the control. IRAK2 overexpression alone inhibited tumor growth, indicating that IRAK2 may function as a tumor suppressor (Figure 4A). We then examined the effect of control and IRAK2-overexpressed mice that received a fraction size of 5 Gy every four days to a cumulative dose of 50 Gy, respectively. After exposure to RT, the tumor volume of IRAK2-overexpressed mice was statistically significantly decreased when compared with that of control ones, implicating that IRAK2 enhances the efficacy of IR treatment in radioresistant tumors (Figure 4B). The increased expressions of cleaved caspase-8 and cleaved caspase-3 were further confirmed by immunofluorescence staining and western blotting on tumor tissues in IRAK2-overexpressed xenografted mice treated with RT (Figures 4C, D).

High IRAK2 Expression Was Associated With Favorable Local Control in Oral Cancer Patients

Finally, we examined the expression of IRAK2 in 41 OSCC patient samples and summarized clinicopathologic factors in Table 1. No statistically significant correlation was found between the level of IRAK2 expression and other clinicopathological variables. Immunohistochemical staining showed IRAK2 expression in the cytoplasm and membrane of OSCC tumor samples (Figure 5A). Kaplan-Meier survival curves was performed to demonstrate that patients with higher IRAK2 expression (i.e., >110) were associated with better local recurrence-free survival than that of those patients with lower expressions (i.e., ≤110; P = 0.055; Figure 5B). Cox proportional hazard regression confirmed this observation (univariate HR, 0.25, being slight in favor of high expression; 95% CI, 0.054 - 1.166; P = 0.055; Figure 5C), particularly after multivariable analysis (multivariate HR, 0.11; 95% CI, 0.016 - 0.760; P = 0.025; Figures 5D, E). Note that seven factors were used for multivariable analysis of local recurrence: age, gender, pathological stage, radiotherapy dose, chemotherapy, the status of surgical margin, and expression level of IRAK2.
DISCUSSION

Radioresistance remains a major obstacle for the radiotherapy treatment of OSCC, leading to post-irradiation recurrence and poor clinical outcomes (24, 25). However, so far, few biomarkers are available for identifying potential responders to RT. Based on RNA-seq analysis, we determined that IRAK2 might be an IR-responsive gene whose expression differed significantly between radiosensitive and radioresistant OSCC cells. We found that IRAK2 was downregulated in a radioresistant OML1-R cell line when compared with its parental OML1 cell line. We further examined the expression of IRAK2 in IR-sensitive OML1 and IR-resistant OML1-R cells and showed that the mRNA and protein expression levels of IRAK2 were increased mainly in OML1 cells after IR exposure; however, there was no difference in IRAK2 level between unirradiated and irradiated OML1-R cells, suggesting that the loss of IRAK2 might be an indicator or possibly contribute to mechanisms of radiation resistance. To further clarify the role of IRAK2 in RT, we overexpressed IRAK2 in OML1-R cell lines. Enhanced IRAK2 expression in OML1-R led to decreased colony formation after IR. Conversely, knocking down IRAK2 increased the post-irradiation survival of OSCC cells. Besides, in vivo, nude mice exposed to RT had smaller tumors after they were injected with IRAK2-overexpressed OML1-R cells. These sets of data strongly suggested that IRAK2 may serve as a potential therapeutic molecular marker for enhancing radiosensitivity and reversing radioresistance. Therefore, we confirmed that IRAK2 acts as a potential regulator of radiation sensitivity for OSCC.

IRAK2, an immune-responsive protein kinase, is a transducer for the IL1/TLR signaling cascade (6, 26, 27). Recent evidence suggests that TLR-dependent mechanisms contribute to radiation-induced anticancer immunity through the induction of genes associated with programmed cell death (28, 29). Mechanistically, TLR is connected through the interaction of an adaptor molecule (i.e., MyD88), which recruits FADD and caspase-8, leading to the activation of caspase-3 to trigger the apoptotic process subsequently (30). For example, BEAS-2B cells (which were derived from human bronchial epithelium transformed) were treated with a TLR3 agonist [i.e., poly(I:C)]; this manipulation was found to induce apoptosis through the interaction of MyD88 with FADD and caspase-8 (31). Besides, TLR2 was also found to potentiate the MyD88-induced caspase-8 apoptotic pathway in human kidney epithelial 293 cells (32). As
a result, IRAK2 demonstrated a mediator of MyD88-dependent signal transduction activation via TLRs (6, 33).

IRAK2 also has been reported to be associated with signaling cell death (34). It could induce apoptosis in bacteria-infected macrophages by targeting the FADD/caspase-8 death signaling pathway (35, 36). Moreover, IRAK2 is required for ER stress-induced increases in IRE1 and CHOP expression, which transduces the death signal in ER stress-mediated apoptosis (9). In the present study, we found that overexpression of IRAK2 significantly increased the apoptotic rate in response to IR through cleavage activation of caspase 8 and caspase 3 in irradiated cells, whereas in the presence of z-IETD-FMK (caspase-8 inhibitor) could significantly decrease IRAK2-induced caspase-8 and caspase-3 cleavage. It suggested that IRAK2-induced apoptosis is dependent on the caspase-8 activation.

On the other hand, IRAK2 knockdown diminished the caspase-8 and caspase-3-mediated apoptosis. These findings indicated that IRAK2 might be a superior target for radiosensitization, triggering apoptosis mainly through the activation of caspase-8 and caspase-3 to increase and restore the sensitivity of radioresistant cells to IR-induced cell killing. However, the significant functional role of IRAK2 in mediating apoptosis and anticancer immunity by TLR signaling needs to be further investigated.

Since few reports have discussed the role of IRAK2 in solid tumors (37), we further evaluated the clinical significance of IRAK2 expression in 41 pathological stage I-II OSCC patients who underwent postoperative radiotherapy. Patients with high IRAK2 expression have been demonstrated to be better local control rates than those with low IRAK2 expression. The limitations of the present study are as follows: the nature of retrospective study design and a relatively small case number. Thus, further studies with a large sample size are required to confirm our results. Taken together, we found that IRAK2 was downregulated in radioresistant OSCC cells. We further determined that enhancing IRAK2 activity led to increasing/restoring radiosensitivity in radioresistant OSCC in vitro and in vivo – and vice versa – operating through a caspase-8/3-
FIGURE 5 | After postoperative radiotherapy, OSCC patients with higher IRAK2 expressions showed better local recurrence-free survival (LRFS) than those with lower IRAK2 expressions. (A) Representative micrographs demonstrated the immunohistochemical (IHC) scores of IRAK2 expression in oral squamous cell carcinoma. (magnification, x200). (B) Kaplan-Meier survival curves represented that patients with higher IRAK2 expressions (i.e., >110) seemingly demonstrated better 5-year LRFS than that of patients with lower expressions (i.e., 87.4% vs. 60.0%; P = 0.055, a statistical trend). (C) Cox proportional hazard regression confirmed this observation (univariate HR 0.25; 95% CI, 0.054 - 1.166; P = 0.055, a statistical trend). (D) Remarkably, after multivariable analysis, the two groups showed a statistically significant difference in terms of post-irradiation LRFS (multivariate HR 0.11; 95% CI, 0.016 - 0.760; P = 0.025). (E) Forest plot of multivariate analysis, depending on the Panel (D) Note that seven factors were used for multivariate analysis of LRFS (Panel C): age, gender, pathological stage, RT dose, chemotherapy, the status of surgical margin, and the expression level of IRAK2.

TABLE 1 | Patient characteristics of 41 oral cancer patients according to the expression level of IRAK2.

| IRAK2 | Low expression (n = 24) | High expression (n = 17) | P value |
|-------|-------------------------|-------------------------|---------|
| Age (years) (mean ± SD) | 51.3 ± 11.4 | 52.7 ± 10.1 | 0.70 |
| RT dose (cGy) (mean ± SD) | 6338.3 ± 1378.4 | 6559.4 ± 1284.8 | 0.61 |
| Gender | | | |
| Male | 23 (96%) | 16 (94%) | 0.80 |
| Female | 1 (4%) | 1 (6%) | |
| Clinical stage | | | |
| I | 8 (33%) | 4 (24%) | 0.88 |
| II | 11 (46%) | 9 (53%) | |
| III | 2 (8%) | 1 (6%) | |
| IV/A/B | 3 (13%) | 3 (18%) | |
| Pathologic stage | | | |
| I | 15 (63%) | 7 (41%) | 0.18 |
| II | 9 (38%) | 10 (59%) | |
| Surgical margin | | | |
| <1 mm | 6 (25%) | 1 (5.9%) | 0.21 |
| ≥1-≤5 mm | 18 (75%) | 16 (94.1%) | |
| Lymphovascular space invasion | | | |
| No | 23 (95.8%) | 14 (82.4%) | 0.29 |
| Yes | 1 (4.2%) | 3 (17.6%) | |
| Perineural invasion | | | |
| No | 22 (91.7%) | 13 (76.5%) | 0.18 |
| Yes | 2 (8.3%) | 4 (23.5%) | |
| Chemotherapy | | | |
| No | 17 (71%) | 10 (59%) | 0.42 |
| Yes | 7 (29%) | 7 (41%) | |

SD, standard deviation; RT, radiotherapy.
According to the principle of surgical oncology and our treatment policy, re-resection was the first treatment of choice for patients who had close-margin (i.e., ≤5 mm) pathology stage I-III OSCC. However, for those patients who had anatomic difficulty on re-resection and who had refusal of re-operation, salvage therapy of radiotherapy with or without chemotherapy was the alternative treatment choice, as that indicated for the above 41 patients.
dependent apoptosis mechanism. Our data suggested that IRAK2 may affect both the developments of intrinsic and irradiation-acquired radioresistance.

The present study is the first report stating that IRAK2 activation may be associated with modulation of radiosensitivity. IRAK2 may facilitate the process of radiation immunity by inducing cancer cells to undergo apoptosis.

CONCLUSIONS

In the present study, we have established a proof-of-concept platform in vivo and in vitro that the potential of IRAK2 may serve as both predictive and therapeutic biomarkers for estimating and manipulating radiation sensitivity in OSCC. Overexpressing IRAK2 increases and restores radiosensitivity in intrinsic and treatment-acquired radioresistant OSCC, respectively. Clinically, high IRAK2 expression predicts better local control in irradiated OSCC patients. However, the real-world clinical treatment utilization of IRAK2 in patients with OSCC remains unknown. Accordingly, further research in targeted gene therapy techniques to assess their efficacy and safety in OSCC is required.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: GEO Series, accession number GSE165585.

REFERENCES

1. Pfister DG, Spencer S, Adelstein D, Adkins Y, Anzai Y, Brizel DM, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2020) 18(7):937–98. doi: 10.6004/jnccn.2020.0031
2. Ishigami T, Uzawa K, Higo M, Nomura H, Saito K, Kato Y, et al. Genes and Molecular Pathways Related to Radiosensitivity of Oral Squamous Cell Carcinoma Cells. Int J Cancer (2007) 120(10):2262–70. doi: 10.1002/ijc.22561
3. Sankuny M, Parikh RA, Lewis DW, Gooding WE, Saunders WS, Gollin SM. Targeted Inhibition of ATR or CHEK1 Reverses Radiosensitivity in Oral Squamous Cell Carcinoma Cells With Distal Chromosome Arm 11q Loss. Genes Chromosomes Cancer (2014) 53(2):129–43. doi: 10.1002/gcc.22125
4. Ge L, Liu S, Xie L, Sang L, Ma C, Li H. Differential mRNA Expression Profiling of Oral Squamous Cell Carcinoma by High-Throughput RNA Sequencing. J BioMed Res (2015) 29(5):397–404. doi: 10.7555/JBR.29.20140088
5. Lin HY, Huang TH, Chan MW. Aberrant Epigenetic Modifications in Radiation-Resistant Head and Neck Cancers. Methods Mol Biol (2015) 1238:321–32. doi: 10.1007/978-1-4939-1804-1_17
6. Meylan E, Tschopp J. IRAK2 Takes its Place in TLR Signaling. Nat Immunol (2008) 9(6):581–2. doi: 10.1038/n免疫.581
7. Rhygas GW, Starczynowski DT. IRAK Signalling in Cancer. Br J Cancer (2015) 112(2):232–7. doi: 10.1038/bjc.2014.513
8. Ruckdeschel K, Mannel O, Schrottner P. P16: A New Tumor Suppressor? The Role of P16 in Cancer. J Immunol (2002) 168(9):4601–11. doi: 10.4049/jimmunol.168.9.4601
9. Benosman S, Ravanant P, Correa RG, Hou YC, Yu M, Gullen MF, et al. Interleukin-1 Receptor-Associated Kinase-2 (IRAK2) is a Critical Mediator of Endoplasmic Reticulum (ER) Stress Signaling. PLoS One (2013) 8(5):e64256. doi: 10.1371/journal.pone.0064256
10. Vollmer S, Strickson S, Zhang T, Gray N, Lee KL, Rao VR, et al. The Mechanism of Activation of IRAK1 and IRAK4 by Interleukin-1 and Toll-like Receptor Agonists. Biochem J (2017) 474(12):2027–38. doi: 10.1042/Bj20170097
11. Liu PH, Shah RB, Li Y, Arcoz A, Ung PM, Ramam R, et al. An IRAK1-PI3K Signalling Axis Drives Intrinsic Tumour Resistance to Radiation Therapy. Nat Cell Biol (2019) 21(2):203–13. doi: 10.1038/s41556-018-0260-7
12. Lin HY, Hung SK, Lee MS, Chiou WY, Huang TT, Tseng CE, et al. DNA Methylation Analysis Identifies Epigenetic Silencing of FHT1 as a Determining Factor for Radiosensitivity in Oral Cancer: An Outcome-Predicting and Treatment-Implicating Study. Oncotarget (2015) 6(2):915–34. doi: 10.18632/oncotarget.2821
13. Lin HY, Huang TT, Lee MS, Huang SK, Lin RL, Tseng CE, et al. Unexpected Close Surgical Margin in Resected Buccal Cancer: Very Close Margin and DAPK Promoter Hypermethylation Predict Poor Clinical Outcomes. Oral Oncol (2013) 49(4):336–44. doi: 10.1016/j.oraloncology.2012.11.005
14. Caudell JJ, Ward MC, Riaz N, Zaken SJ, Awan MJ, Dunlap NE, et al. Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-Institution Analysis. Int J Radiat Oncol Biol Phys (2018) 100(3):606–17. doi: 10.1016/j.ijrobp.2017.11.036
15. Halperin EC, Wazer DE, Perez CA, Brady LW. P16: A New Tumor Suppressor? The Role of P16 in Cancer. J Immunol (2002) 168(9):4601–11. doi: 10.4049/jimmunol.168.9.4601
16. Benosman S, Ravanant P, Correa RG, Hou YC, Yu M, Gullen MF, et al. Interleukin-1 Receptor-Associated Kinase-2 (IRAK2) is a Critical Mediator of Endoplasmic Reticulum (ER) Stress Signaling. PLoS One (2013) 8(5):e64256. doi: 10.1371/journal.pone.0064256
17. Vollmer S, Strickson S, Zhang T, Gray N, Lee KL, Rao VR, et al. The Mechanism of Activation of IRAK1 and IRAK4 by Interleukin-1 and Toll-like Receptor Agonists. Biochem J (2017) 474(12):2027–38. doi: 10.1042/Bj20170097
18. Liu PH, Shah RB, Li Y, Arcoz A, Ung PM, Ramam R, et al. An IRAK1-PI3K Signalling Axis Drives Intrinsic Tumour Resistance to Radiation Therapy. Nat Cell Biol (2019) 21(2):203–13. doi: 10.1038/s41556-018-0260-7
19. Lin HY, Hung SK, Lee MS, Chiou WY, Huang TT, Tseng CE, et al. DNA Methylation Analysis Identifies Epigenetic Silencing of FHT1 as a Determining Factor for Radiosensitivity in Oral Cancer: An Outcome-Predicting and Treatment-Implicating Study. Oncotarget (2015) 6(2):915–34. doi: 10.18632/oncotarget.2821
20. Lin HY, Huang TT, Lee MS, Huang SK, Lin RL, Tseng CE, et al. Unexpected Close Surgical Margin in Resected Buccal Cancer: Very Close Margin and DAPK Promoter Hypermethylation Predict Poor Clinical Outcomes. Oral Oncol (2013) 49(4):336–44. doi: 10.1016/j.oraloncology.2012.11.005
21. Caudell JJ, Ward MC, Riaz N, Zaken SJ, Awan MJ, Dunlap NE, et al. Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-Institution Analysis. Int J Radiat Oncol Biol Phys (2018) 100(3):606–17. doi: 10.1016/j.ijrobp.2017.11.036
22. Halperin EC, Wazer DE, Perez CA, Brady LW. P16: A New Tumor Suppressor? The Role of P16 in Cancer. J Immunol (2002) 168(9):4601–11. doi: 10.4049/jimmunol.168.9.4601
23. Benosman S, Ravanant P, Correa RG, Hou YC, Yu M, Gullen MF, et al. Interleukin-1 Receptor-Associated Kinase-2 (IRAK2) is a Critical Mediator of Endoplasmic Reticulum (ER) Stress Signaling. PLoS One (2013) 8(5):e64256. doi: 10.1371/journal.pone.0064256
Yu et al. IRAK2 Enhances Radiosensitivity

25. Liu L, Zhu Y, Liu AM, Feng Y, Chen Y. Long Noncoding RNA LINC00511

24. Smith BD, Haffty BG. Molecular Markers as Prognostic Factors for Local

23. Kunogi H, Sakanishi T, Sueyoshi N, Sasai K. Prediction of Radiosensitivity Using

22. Boumiza A, Zemni R, Sghiri R, Idriss N, Hassine HB, Chabchoub E, et al.

26. Wang H, Flannery SM, Dickhofer S, Huhn S, George J, Kubarenko AV, et al. A

28. Trapani S, Manicone M, Sikokis A, D'Abbrero N, Salafot F, Ceccone G, et al.

27. Lin SC, Lo YC, Wu H. Helical Assembly in the MyD88-IRAK4-IRAK2

29. Ratikan JA, Micewicz ED, Xie MW, Schaue D. Radiation Takes its Toll.

30. Cen X, Liu S, Cheng K. The Role of Toll-Like Receptor in Inflammation and

Sarcomas is Associated With Improved Survival: Analysis of the National Cancer Database. Head Neck (2019) 41(6):1873–9. doi: 10.1002/hed.25619

Greene FL. AJCC Cancer Staging Atlas. New York, NY: Springer (2006).

Hsieh MY, Chen G, Chang DC, Chen SY, Chen MK. The Impact of Metronomic Adjunct Chemotherapy in Patients With Advanced Oral Cancer. Ann Surg Oncol (2018) 25(7):2091–7. doi: 10.1245/s10434-018-6497-3

Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic Assay of Cells In Vitro. Nat Protoc (2006) 1(5):2315–9. doi: 10.1038/nprot.2006.339

Yu CC, Chen CA, Fu SL, Lin HY, Lee MS, Chiou WY, et al. Andrographolide Enhances the Anti-Metastatic Effect of Radiation in Ras-transformed Cells Via Suppression of ERK-mediated MMP-2 Activity. PloS One (2018) 13(10): e0205666. doi: 10.1371/journal.pone.0205666

Bouniaza A, Zennri R, Ghiri R, Idriess N, Hassine HB, Chalchoub E, et al. IRAK2 is Associated With Systemic Lupus Erythematosus Risk. Clin Rheumatol (2020) 39(2):419–24. doi: 10.1007/s10067-019-04781-1

Kunogi H, Sakanishi T, Sueyoshi N, Sasai K. Prediction of Radiosensitivity Using Phosphorylation of Histone H2AX and Apoptosis in Human Tumor Cell Lines. Int J Radiat Biol (2014) 90(7):587–93. doi: 10.3109/09553002.2014.907518

Smith BD, Haffty BG. Molecular Markers as Prognostic Factors for Local Recurrence and Radioreistance in Head and Neck Squamous Cell Carcinoma. Radiat Oncol Invest (1999) 7(3):125–44. doi: 10.1002/(SICI) 1520-6823(1999)7:3<125::AID-ROI1>3.0.CO;2-W

Liu L, Zhu Y, Liu AM, Feng Y, Chen Y. Long Noncoding RNA LINC00511 Involves in Breast Cancer Recurrence and Radiosistance by Regulating STXB4 Expression Via Mir-185. Eur Rev Med Pharmacol Sci (2019) 23(17):4757–68. doi: 10.26355/eurrev_201909_18855

Wang H, Flannery SM, Dickhofer S, Huhn S, George J, Kubarenko AV, et al. A Coding IRAK2 Protein Variant Compromises Toll-like Receptor (TLR) Signaling and is Associated With Colorectal Cancer Survival. J Biol Chem (2014) 289(33):23123–31. doi: 10.1074/jbc.M113.492934

Lin SC, Lo YC, Wu H. Helical Assembly in the MDR88-IRAK4-IRAK2 Complex in TLR/IL-1R Signalling. Nature (2010) 465(7300):885–90. doi: 10.1038/nature09121

Trapani S, Manicone M, Sikokis A, D'Abbrero N, Salafot F, Ceccone G, et al. Effectiveness and Safety of "Real" Concurrent Stereotactic Radiotherapy and Immunotherapy in Metastatic Solid Tumors: A Systematic Review. Crit Rev Oncol Hematol (2019) 142:9–15. doi: 10.1016/j.critrevonc.2019.07.006

Ratikan JA, Micewicz ED, Xie MW, Schaue D. Radiation Takes its Toll. Cancer Lett (2015) 368(2):238–45. doi: 10.1016/j.canlet.2015.03.031

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Yu, Chan, Lin, Chiou, Lin, Chen, Lee, Chi, Chen, Huang, Chew, Hsu, Yang and Hung. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.